These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

418 related items for PubMed ID: 26828016

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. MiR-608 regulating the expression of ribonucleotide reductase M1 and cytidine deaminase is repressed through induced gemcitabine chemoresistance in pancreatic cancer cells.
    Rajabpour A, Afgar A, Mahmoodzadeh H, Radfar JE, Rajaei F, Teimoori-Toolabi L.
    Cancer Chemother Pharmacol; 2017 Oct; 80(4):765-775. PubMed ID: 28887583
    [Abstract] [Full Text] [Related]

  • 3. Involvement of ribonucleotide reductase M1 subunit overexpression in gemcitabine resistance of human pancreatic cancer.
    Nakahira S, Nakamori S, Tsujie M, Takahashi Y, Okami J, Yoshioka S, Yamasaki M, Marubashi S, Takemasa I, Miyamoto A, Takeda Y, Nagano H, Dono K, Umeshita K, Sakon M, Monden M.
    Int J Cancer; 2007 Mar 15; 120(6):1355-63. PubMed ID: 17131328
    [Abstract] [Full Text] [Related]

  • 4. YBX1 as a therapeutic target to suppress the LRP1-β-catenin-RRM1 axis and overcome gemcitabine resistance in pancreatic cancer.
    Li B, Xing F, Wang J, Wang X, Zhou C, Fan G, Zhuo Q, Ji S, Yu X, Xu X, Qin Y, Li Z.
    Cancer Lett; 2024 Oct 10; 602():217197. PubMed ID: 39216548
    [Abstract] [Full Text] [Related]

  • 5. miR-125a-3p is responsible for chemosensitivity in PDAC by inhibiting epithelial-mesenchymal transition via Fyn.
    Liu G, Ji L, Ke M, Ou Z, Tang N, Li Y.
    Biomed Pharmacother; 2018 Oct 10; 106():523-531. PubMed ID: 29990840
    [Abstract] [Full Text] [Related]

  • 6. An increase in the expression of ribonucleotide reductase large subunit 1 is associated with gemcitabine resistance in non-small cell lung cancer cell lines.
    Davidson JD, Ma L, Flagella M, Geeganage S, Gelbert LM, Slapak CA.
    Cancer Res; 2004 Jun 01; 64(11):3761-6. PubMed ID: 15172981
    [Abstract] [Full Text] [Related]

  • 7. Potent effect of adenoviral vector expressing short hairpin RNA targeting ribonucleotide reductase large subunit M1 on cell viability and chemotherapeutic sensitivity to gemcitabine in non-small cell lung cancer cells.
    Tokunaga Y, Liu D, Nakano J, Zhang X, Nii K, Go T, Huang CL, Yokomise H.
    Eur J Cancer; 2015 Nov 01; 51(16):2480-9. PubMed ID: 26254808
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Ribonucleotide reductase subunit M1 is a possible chemoresistance marker to gemcitabine in biliary tract carcinoma.
    Ohtaka K, Kohya N, Sato K, Kitajima Y, Ide T, Mitsuno M, Miyazaki K.
    Oncol Rep; 2008 Aug 01; 20(2):279-86. PubMed ID: 18636187
    [Abstract] [Full Text] [Related]

  • 11. Leptin-elicited miRNA-342-3p potentiates gemcitabine resistance in pancreatic ductal adenocarcinoma.
    Ma L, Fan Z, Du G, Wang H.
    Biochem Biophys Res Commun; 2019 Feb 12; 509(3):845-853. PubMed ID: 30638935
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. The MEK1/2 Inhibitor Pimasertib Enhances Gemcitabine Efficacy in Pancreatic Cancer Models by Altering Ribonucleotide Reductase Subunit-1 (RRM1).
    Vena F, Li Causi E, Rodriguez-Justo M, Goodstal S, Hagemann T, Hartley JA, Hochhauser D.
    Clin Cancer Res; 2015 Dec 15; 21(24):5563-77. PubMed ID: 26228206
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Prognostic Implications of Expression Profiling for Gemcitabine-Related Genes (hENT1, dCK, RRM1, RRM2) in Patients With Resectable Pancreatic Adenocarcinoma Receiving Adjuvant Chemotherapy.
    Sierzega M, Pach R, Kulig P, Legutko J, Kulig J.
    Pancreas; 2017 Dec 15; 46(5):684-689. PubMed ID: 28196013
    [Abstract] [Full Text] [Related]

  • 16. MicroRNA-34a Alleviates Gemcitabine Resistance in Pancreatic Cancer by Repression of Cancer Stem Cell Renewal.
    Pan Y, Li K, Tao X, Zhao Y, Chen Q, Li N, Liu J, Go VLW, Guo J, Gao G, Xiao GG.
    Pancreas; 2021 Oct 01; 50(9):1260-1266. PubMed ID: 34860809
    [Abstract] [Full Text] [Related]

  • 17. ERK-mediated transcriptional activation of Dicer is involved in gemcitabine resistance of pancreatic cancer.
    Su YH, Hsu TW, Chen HA, Su CM, Huang MT, Chuang TH, Leo Su J, Hsieh CL, Chiu CF.
    J Cell Physiol; 2021 Jun 01; 236(6):4420-4434. PubMed ID: 33184874
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Gemcitabine chemoresistance and molecular markers associated with gemcitabine transport and metabolism in human pancreatic cancer cells.
    Nakano Y, Tanno S, Koizumi K, Nishikawa T, Nakamura K, Minoguchi M, Izawa T, Mizukami Y, Okumura T, Kohgo Y.
    Br J Cancer; 2007 Feb 12; 96(3):457-63. PubMed ID: 17224927
    [Abstract] [Full Text] [Related]

  • 20. Chemosensitization and inhibition of pancreatic cancer stem cell proliferation by overexpression of microRNA-205.
    Chaudhary AK, Mondal G, Kumar V, Kattel K, Mahato RI.
    Cancer Lett; 2017 Aug 28; 402():1-8. PubMed ID: 28536008
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.